Literature DB >> 7092350

Carcinoid syndrome from gastrointestinal carcinoids without liver metastasis.

J M Feldman, R S Jones.   

Abstract

Although patients with bronchial and ovarian carcinoid tumors can develop the carcinoid syndrome (diarrhea and/or flushing) in the absence of hepatic metastasis, it is believed that development of the carcinoid syndrome in patients with carcinoid tumors of gastrointestinal origin occurs only after the patient has hepatic metastasis. This is explained by hepatic inactivation of most of the serotonin in the portal circulation or by the fact that hepatic metastases are larger than the primary tumor in the gastrointestinal tract. Three patients with ileal and jejunal carcinoid tumors who developed the carcinoid syndrome without obvious hepatic metastasis are described. Two of the patients had intra-abdominal, but extrahepatic, metastasis that probably drained directly into the systemic circulation. The third patient had an ileal carcinoid with clinical involvement limited to adjacent mesenteric lymph nodes. Following resection of her tumor, her urinary 5-HIAA excretion and platelet serotonin level returned to normal, and her attacks of carcinoid flushing virtually ceased. She has occasional spells of "blushing" that are thought to be benign; however, further close follow-up study will be needed to be certain that she is free of disease. It is suggested that each patient with the carcinoid syndrome be evaluated with CT and technetium-99 pertechnetate liver scans. If there is no liver involvement detected with these studies, one should consider hepatic arteriogram or laparotomy to determine if the patient's tumor might be totally resectable.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7092350      PMCID: PMC1352493          DOI: 10.1097/00000658-198207000-00008

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  9 in total

1.  Increased sensitivity of the enzymatic isotopic assay of histamine: measurement of histamine in plasma and serum.

Authors:  R E Shaff; M A Beaven
Journal:  Anal Biochem       Date:  1979-04-15       Impact factor: 3.365

2.  Pressor amines and the carcinoid flush.

Authors:  R J LEVINE; A SJOERDSMA
Journal:  Ann Intern Med       Date:  1963-05       Impact factor: 25.391

3.  The identification of 5-hydroxy-3-indoleacetic acid in normal urine and a method for its assay.

Authors:  S UDENFRIEND; E TITUS; H WEISSBACH
Journal:  J Biol Chem       Date:  1955-10       Impact factor: 5.157

4.  Plasma para-chlorophenylalanine measurements with gas-liquid chromatography. Methodological and pharmacological studies.

Authors:  J M Feldman; J Admiraal; J W Plonk; J B Sidbury
Journal:  Biochem Med       Date:  1977-06

5.  Carcinoid tumor-cure by irradiation.

Authors:  A Gaitan-Gaitan; W D Rider; R S Bush
Journal:  Int J Radiat Oncol Biol Phys       Date:  1975 Oct-Nov       Impact factor: 7.038

6.  Streptozotocin treatment of metastatic carcinoid tumors.

Authors:  J M Feldman; K E Quickel; R L Marecek; H E Lebovitz
Journal:  South Med J       Date:  1972-11       Impact factor: 0.954

7.  Angiographic evaluation of carcinoid tumors of the small intestine: the value of epinephrine.

Authors:  H M Goldstein; M Miller
Journal:  Radiology       Date:  1975-04       Impact factor: 11.105

8.  Radioenzymatic assay of platelet serotonin, dopamine and norepinephrine in subjects with normal and increased serotonin production.

Authors:  J M Feldman; J A Davis
Journal:  Clin Chim Acta       Date:  1981-02-05       Impact factor: 3.786

9.  Gastrointestinal carcinoids and the malignant carcinoid syndrome.

Authors:  H Beaton; W Homan; P Dineen
Journal:  Surg Gynecol Obstet       Date:  1981-03
  9 in total
  10 in total

1.  Gastrointestinal carcinoids: characterization by site of origin and hormone production.

Authors:  M W Onaitis; P M Kirshbom; T Z Hayward; F J Quayle; J M Feldman; H F Seigler; D S Tyler
Journal:  Ann Surg       Date:  2000-10       Impact factor: 12.969

2.  Occult retroperitoneal carcinoid tumor with flushing and solitary lung metastasis.

Authors:  J A Jackson; H D Shipman
Journal:  West J Med       Date:  1989-10

3.  Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival.

Authors:  I Norheim; K Oberg; E Theodorsson-Norheim; P G Lindgren; G Lundqvist; A Magnusson; L Wide; E Wilander
Journal:  Ann Surg       Date:  1987-08       Impact factor: 12.969

Review 4.  Carcinoid-syndrome: recent advances, current status and controversies.

Authors:  Tetsuhide Ito; Lingaku Lee; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2018-02       Impact factor: 3.243

5.  Carcinoid syndrome without liver metastasis.

Authors:  J Hossain; I al-Mofleh; R Tandon; N M Dhahada
Journal:  Postgrad Med J       Date:  1989-08       Impact factor: 2.401

6.  Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study.

Authors:  Daniel M Halperin; Chan Shen; Arvind Dasari; Ying Xu; Yiyi Chu; Shouhao Zhou; Ya-Chen Tina Shih; James C Yao
Journal:  Lancet Oncol       Date:  2017-02-24       Impact factor: 41.316

7.  Carcinoid syndrome from a carcinoid tumor of the pancreas without liver metastases: A case report and literature review.

Authors:  Nikolaos Zavras; Demetrios Schizas; Nikolaos Machairas; Vasileia Damaskou; Nikolaos Economopoulos; Anastasios Machairas
Journal:  Oncol Lett       Date:  2017-02-06       Impact factor: 2.967

8.  Carcinoid tumors of the appendix.

Authors:  A Roggo; W C Wood; L W Ottinger
Journal:  Ann Surg       Date:  1993-04       Impact factor: 12.969

9.  Metastatic small bowel neuroendocrine tumour with bilateral carcinoid heart disease.

Authors:  V Jahagirdar; Ali Kamal; R Steeds; John Ayuk
Journal:  BMJ Case Rep       Date:  2016-02-03

10.  Clinicopathological and Perioperative Outcome of Appendiceal Tumors: Case Review of 31 Patients.

Authors:  Haroutioun Boyajian; Vanessa Majeski; Alicia Flores; David Sturtz; Fadi Baidoun; Mohammed Dughayli
Journal:  Spartan Med Res J       Date:  2020-10-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.